To screen or nor to screen: the prostate cancer dilemma

To screen or not to screen: the prostate cancer dilemma

The European Randomized Study of Screening for Prostate (ERSPC) has updated their previous seminal report on prostate cancer mortality comparing screened men to controls. Now with 13 years follow-up, the rate ratio of prostate cancer mortality was 0.79 favoring the screened population. The authors concluded that there was a "substantial reduction in prostate cancer mortality attributable to tes...

To screen or not to screen: ongoing debate in the early detection of prostate cancer.

Debate about the use of prostate-specific antigen (PSA) tests to screen prostate cancer in men is ongoing. Prostate cancer is the most common cancer after skin cancer in men and the second most deadly after lung cancer. An elevated PSA level can lead to this cancer's diagnosis and treatment even before the onset of symptoms. However, other causes also can create a high PSA level, which may lead...

[EAU guidelines for prostate cancer: to screen or not to screen?].

Since the implementation of serum prostate-specific antigen (PSA) as a screening tool revealed acceptable results in reducing prostate cancer specific mortality, demonstrated in the US Prostate, Lung, Colorectal and Ovarian cancer screening trial (PLCO) and the European Randomized Study of Screening for Prostate Cancer (ERSPC), substantial aspects of its utilization should be taken into closer ...

Colorectal cancer: to screen or not to screen?

Familial Pancreatic Cancer: To Screen or not to Screen?

In this issue of EBioMedicine, Pandharipande and colleagues report but at the same time represent a danger due to the inherent complicaimportant data that may well assist the decision-making process when screening families at risk for pancreatic ductal adenocarcinoma (PDAC) (Pandharipande et al., 2015). The aim of the study was to compare, using a simulation model, the effectiveness of differen...